Apokyn Bertek Pharmaceuticals - Treatment for Parkinson’s Disease

Apokyn (apomorphine hydrochloride injection) is the first and only therapy in the United States for the acute, intermittent treatment of hypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) associated with advanced Parkinson’s disease.

Posted: April 2004

Apokyn (apomorphine) FDA Approval History

More News Resources

Drug Status

Availability Rx Prescription only

Pregnancy Category C Risk cannot be ruled out

CSA Schedule N Not a controlled drug

Approval History Calendar Drug history at FDA

Recently Approved

Haegarda Haegarda (C1 esterase inhibitor (human)) is a low-volume subcutaneous (SC) C1-esterase inhibitor...
Mydayis Mydayis (amphetamine mixed salts) is a central nervous system (CNS) stimulant indicated for the...
Baxdela Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute...
Cotempla XR-ODT Cotempla XR-ODT (methylphenidate) is a once-daily, extended-release, orally disintegrating tablet...

Available RSS Feeds

Select any link below to view the RSS feed.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated June 2nd, 2017), Cerner Multum™ (updated June 5th, 2017), Wolters Kluwer™ (updated June 6th, 2017) and others. To view content sources and attributions, please refer to our editorial policy.

Apokyn Bertek Pharmaceuticals - Treatment for Parkinson’s Disease

More News Resources

Drug Status

Support

About

Terms & Privacy

Apokyn Bertek Pharmaceuticals - Treatment for Parkinson’s Disease

More News Resources

Drug Status

Drugs.com Mobile Apps

Support

About

Terms & Privacy

Hide